Argenx files for U.S. stock listing

March 2, 2017 News BioVox

argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States.

The timing, number of ordinary shares and price of the proposed offering have not yet been determined.

More news on Argenx

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts